Harel Insurance Investments & Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-200	Closed	-$15K	–	724
2020 Q3	$15K	Buy	+200	New	+$20.2K	﹤0.01%	537
2018 Q4	–	Sell	-3,846	Closed	-$373K	–	467
2018 Q3	$373K	Sell	3,846 -1,754	-31%	-$175K	0.02%	164
2018 Q2	$528K	Buy	+5,600	New	+$490K	0.03%	123
2017 Q1	–	Sell	-110	Closed	-$9K	–	424
2016 Q4	$9K	Sell	110 -400	-78%	-$34.4K	﹤0.01%	305
2016 Q3	$47K	Sell	510 -20	-4%	-$1.88K	0.01%	226
2016 Q2	$41K	Hold	530	–	–	﹤0.01%	370
2016 Q1	$44K	Buy	530 +232	+78%	+$18.9K	0.01%	219
2015 Q4	$31K	Buy	+298	New	+$31.1K	﹤0.01%	223

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Harel Insurance Investments & Financial Services's BMRN Position: Q4 2020 in Review

Harel Insurance Investments & Financial Services sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 200 shares — an estimated $15K sold.

Harel Insurance Investments & Financial Services first reported a position in BMRN in Q4 2015 and held it in 8 quarters. The position peaked at $528K in Q2 2018. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

Harel Insurance Investments & Financial Services reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Harel Insurance Investments & Financial Services sold 200 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $15K.
Harel Insurance Investments & Financial Services first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 8 quarters.
Harel Insurance Investments & Financial Services's BioMarin Pharmaceuticals position peaked at $528K in Q2 2018.
538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q4 2020, filed 26 Jan 2021.